Center for Comprehensive Urologic Oncology, University of Southern California Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Center for Comprehensive Urologic Oncology, University of Southern California Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California.
J Urol. 2014 Sep;192(3):682-8. doi: 10.1016/j.juro.2014.03.112. Epub 2014 Apr 3.
Inferior vena cava tumor thrombectomy requires experienced surgical teams due to complex hemodynamic considerations. The teams often use vascular bypass techniques that introduce additional risk. Inferior vena caval control in the pericardium obviates the need for cardiopulmonary bypass. We reviewed our experience with intrapericardial control during inferior vena caval tumor thrombectomy to evaluate perioperative outcomes and determine factors associated with overall survival.
We retrospectively reviewed the records of 87 patients who underwent nephrectomy with inferior vena caval tumor thrombectomy using intrapericardial inferior vena caval control from 1978 to 2012. This technique was performed in all 43 and 35 cases of intrahepatic and supradiaphragmatic thrombi, respectively, and in 9 select cases of intra-atrial thrombi. Patient demographics, operative variables and postoperative outcomes were examined. Multivariate regression analysis was used to determine associations between clinical variables and overall survival.
Mortality 30 days perioperatively was 9.2% and the incidence of high grade complications was 19.5%. Median survival was 3.1 and 2.5 years in patients with pT3bN0 and pT3cN0, respectively. Extended regional lymphadenectomy, which was performed in all cases, revealed nodal metastasis in 38%. On multivariate analysis ECOG greater than 2 and pT3c stage were associated with worse survival. Histological grade, perinephric fat invasion and lymph node involvement were not associated with worse survival.
Intrapericardial control of the inferior vena cava enables a single surgical team to safely perform tumor thrombectomy for intrahepatic and supradiaphragmatic thrombi, eliminating the risk and morbidity related to cardiopulmonary bypass. Although supradiaphragmatic extent and ECOG greater than 2 are associated with worse survival, complete resection with lymphadenectomy can allow for long-term survival in patients with locally advanced disease.
下腔静脉肿瘤血栓切除术需要有经验的手术团队,因为这涉及到复杂的血液动力学考虑因素。这些团队通常使用血管旁路技术,这会带来额外的风险。在心包内控制下腔静脉可以避免心肺旁路的需要。我们回顾了我们在经心包内控制下进行下腔静脉肿瘤血栓切除术的经验,以评估围手术期结果并确定与总生存相关的因素。
我们回顾性分析了 1978 年至 2012 年间 87 例接受经心包内下腔静脉肿瘤血栓切除术的患者的记录,这些患者均采用心包内下腔静脉控制。该技术分别用于 43 例和 35 例肝内和膈上血栓,以及 9 例选择性心房内血栓。检查了患者的人口统计学、手术变量和术后结果。采用多变量回归分析确定临床变量与总生存之间的关联。
术后 30 天死亡率为 9.2%,高级别并发症发生率为 19.5%。pT3bN0 和 pT3cN0 患者的中位生存期分别为 3.1 年和 2.5 年。在所有病例中均进行了广泛的区域淋巴结切除术,发现 38%的病例有淋巴结转移。多变量分析显示,ECOG 大于 2 和 pT3c 期与生存较差相关。组织学分级、肾周脂肪浸润和淋巴结受累与生存较差无关。
心包内下腔静脉控制使单一手术团队能够安全地进行肝内和膈上血栓的肿瘤血栓切除术,消除心肺旁路相关的风险和发病率。尽管膈上范围和 ECOG 大于 2 与生存较差相关,但完全切除和淋巴结清扫可以使局部晚期疾病患者获得长期生存。